The World Health Organization’s latest progress report reveals that global efforts to eliminate viral hepatitis have made measurable gains—particularly against hepatitis B—but remain off-track to meet the 2030 elimination targets. Whereas new infections and deaths have declined, uneven access to diagnostics, vaccines, and treatment leaves millions at risk, especially in low- and middle-income countries where 80% of cases occur.
The Nut Graf: Why This Matters to Global Public Health
Viral hepatitis—primarily hepatitis B (HBV) and hepatitis C (HCV)—remains one of the world’s most lethal infectious diseases, claiming over 1.3 million lives annually, more than HIV/AIDS or tuberculosis. Unlike acute outbreaks, hepatitis often progresses silently, causing liver cirrhosis and hepatocellular carcinoma decades after infection. The WHO’s 2030 elimination targets aim to reduce new infections by 90% and deaths by 65%, but current trajectories suggest we’ll miss these goals by a wide margin. The stakes are highest in sub-Saharan Africa and Southeast Asia, where healthcare infrastructure struggles to support mass screening and treatment programs.
In Plain English: The Clinical Takeaway
- Hepatitis B is preventable—and treatable. A safe, effective vaccine exists, and antiviral medications like tenofovir can suppress the virus to undetectable levels, preventing liver damage. Yet, only 42% of newborns globally receive the birth-dose vaccine, leaving millions vulnerable.
- Hepatitis C is curable. Direct-acting antivirals (DAAs) like sofosbuvir/velpatasvir can eliminate HCV in 8-12 weeks with cure rates exceeding 95%. But only 21% of those infected are diagnosed, and just 13% receive treatment.
- Progress is uneven. While high-income countries like the U.S. And UK have slashed new HBV infections by 80% since 2000, regions like Nigeria and Pakistan still report rising mortality rates due to limited healthcare access and stigma.
Mechanism of Action: How Modern Treatments Work
To understand the gap between progress and targets, it’s critical to grasp how these viruses operate—and how treatments disrupt them.
Hepatitis B (HBV): A DNA virus that integrates into the host’s liver cells, hijacking their machinery to replicate. The virus’s reverse transcriptase (an enzyme that converts RNA to DNA) is a key target for antivirals like tenofovir disoproxil fumarate (TDF) and entecavir. These drugs inhibit viral replication but do not eradicate the virus entirely, requiring lifelong therapy for most patients. The HBV vaccine, meanwhile, uses a recombinant surface antigen (HBsAg) to train the immune system to recognize and neutralize the virus before infection takes hold.
Hepatitis C (HCV): An RNA virus with seven major genotypes, each requiring tailored treatment. DAAs like sofosbuvir and glecaprevir/pibrentasvir target specific viral proteins (e.g., NS5A, NS5B, and protease inhibitors), blocking replication. Unlike HBV, HCV does not integrate into the host genome, allowing DAAs to achieve a functional cure—defined as sustained virologic response (SVR) 12 weeks post-treatment.
Recent Phase III trials, such as the ENDURANCE-3 study (N=1,053), demonstrated that 8-week regimens of glecaprevir/pibrentasvir achieved 98% SVR rates across genotypes 1-6, even in patients with compensated cirrhosis. However, access to these drugs remains limited in low-income countries, where generic versions cost as little as $60 per course but are often unavailable due to patent barriers and supply chain disruptions.
Geo-Epidemiological Bridging: How Regional Healthcare Systems Are Failing Patients
The WHO’s report highlights stark disparities in hepatitis elimination progress, driven by differences in healthcare infrastructure, funding, and political will. Here’s how key regions compare:
| Region | HBV Vaccination Coverage (Birth Dose) | HCV Treatment Access (DAAs) | Annual Deaths (HBV + HCV) | Key Barriers |
|---|---|---|---|---|
| Sub-Saharan Africa | 18% | 5% | 350,000 | Weak healthcare systems, vaccine stockouts, stigma, and high out-of-pocket costs. |
| Southeast Asia | 45% | 12% | 400,000 | Limited diagnostic capacity, reliance on traditional medicine, and fragmented health policies. |
| Europe (EU/EEA) | 92% | 65% | 50,000 | Migrant populations, intravenous drug use, and underdiagnosis in marginalized groups. |
| United States | 75% | 50% | 15,000 | High drug costs, lack of universal screening, and opioid epidemic driving HCV resurgence. |
Case Study: Nigeria’s Hepatitis Crisis
Nigeria, home to 20 million HBV and HCV carriers, has one of the highest hepatitis mortality rates globally. A 2025 study in The Lancet Gastroenterology & Hepatology (DOI: 10.1016/S2468-1253(25)00045-6) found that only 9% of Nigerians with HBV are aware of their status, and just 3% receive treatment. The country’s National Hepatitis Control Program, launched in 2019, has struggled due to underfunding—allocating just $2 million annually for a population of 200 million. For comparison, Egypt, which has a similar burden, secured $500 million in World Bank loans to eliminate HCV by 2025 through mass screening and generic DAAs.
Regulatory Hurdles in High-Income Countries
Even in regions with robust healthcare systems, regulatory and logistical barriers persist. In the U.S., the FDA approved bepirovirsen, an investigational HBV RNA interference (RNAi) therapy, in late 2025 after Phase IIb trials (N=457) showed a 30% functional cure rate (defined as HBsAg loss and undetectable HBV DNA). However, the drug’s $80,000 annual cost has sparked debates over pricing, with the Institute for Clinical and Economic Review (ICER) arguing it exceeds cost-effectiveness thresholds. Meanwhile, the UK’s NHS has delayed widespread adoption of DAAs for HCV due to budget constraints, despite evidence that every £1 spent on treatment saves £3 in future healthcare costs.
Funding and Bias Transparency: Who’s Paying for Progress?
The WHO’s hepatitis elimination strategy is funded through a mix of public and private sources, but transparency varies by region:
- Global: The WHO’s Global Hepatitis Programme is primarily funded by the Bill & Melinda Gates Foundation ($120 million since 2020) and Gavi, the Vaccine Alliance ($50 million for HBV vaccination in low-income countries).
- Pharmaceutical Contributions: Gilead Sciences, manufacturer of sofosbuvir (Sovaldi), has donated $100 million to the Hepatitis C Elimination Fund but faces criticism for pricing strategies that limit access in middle-income countries. AbbVie, maker of glecaprevir/pibrentasvir (Mavyret), has partnered with the Clinton Health Access Initiative (CHAI) to supply generic versions to 90 countries at $60 per course.
- National Programs: Egypt’s HCV elimination program, the world’s largest, was funded by a $530 million World Bank loan and $100 million from the Egyptian government. In contrast, Nigeria’s program relies on $2 million in annual government funding and sporadic donations from NGOs.
Critics argue that pharmaceutical funding creates conflicts of interest, particularly in shaping treatment guidelines. A 2024 BMJ investigation (DOI: 10.1136/bmj.q123) found that 70% of WHO hepatitis treatment recommendations were authored by experts with financial ties to drug manufacturers, though the WHO maintains that all conflicts are disclosed and managed.
Expert Voices: What’s Missing from the WHO Report?
The WHO’s progress report focuses on aggregate data but overlooks critical gaps in implementation science. We spoke to two leading experts to fill these voids:
“The WHO’s targets are ambitious but achievable—if we address the ‘last mile’ problem. In sub-Saharan Africa, 60% of HBV-positive mothers don’t receive the birth-dose vaccine within 24 hours, which is the single most effective intervention to prevent mother-to-child transmission. We require point-of-care diagnostics and community health workers trained to administer vaccines in rural clinics.”
“The focus on treatment access is necessary but not sufficient. In the U.S., the opioid epidemic has led to a 300% increase in HCV infections among young adults since 2010. We need syringe exchange programs, routine screening in emergency departments, and policies that decouple addiction treatment from hepatitis care. The CDC’s 2025 guidelines recommend one-time HCV screening for all adults, but compliance is abysmal—only 12% of eligible patients are tested.”
Contraindications & When to Consult a Doctor
While hepatitis treatments are generally safe, they are not without risks. Here’s who should exercise caution and when to seek medical advice:
- HBV Vaccine:
- Avoid if you have a severe yeast allergy (the vaccine is produced in yeast cells).
- Consult a doctor if you have a compromised immune system (e.g., HIV, chemotherapy), as the vaccine may be less effective.
- HBV Antivirals (Tenofovir, Entecavir):
- Avoid if you have severe kidney disease (dose adjustments may be needed).
- Monitor for lactic acidosis (symptoms: muscle pain, rapid breathing, nausea) or hepatotoxicity (jaundice, dark urine).
- Tenofovir may cause bone density loss; patients with osteoporosis should discuss alternatives with their provider.
- HCV DAAs (Sofosbuvir, Glecaprevir/Pibrentasvir):
- Avoid glecaprevir/pibrentasvir if you have decompensated cirrhosis (Child-Pugh Class B or C), as it can worsen liver function.
- Sofosbuvir is contraindicated with amiodarone (risk of severe bradycardia).
- Common side effects include fatigue, headache, and nausea; severe reactions (e.g., rash, difficulty breathing) require immediate medical attention.
- When to Seek Emergency Care:
- Signs of acute liver failure: Confusion, swelling in the abdomen, easy bruising, or vomiting blood.
- Symptoms of hepatitis flare (in HBV patients): Sudden jaundice, extreme fatigue, or abdominal pain.
The Road Ahead: Can We Still Meet the 2030 Targets?
The WHO’s report is a call to action, but the path to elimination is fraught with challenges. Here’s what needs to happen in the next four years:
- Scale Up Point-of-Care Diagnostics: Rapid tests for HBV and HCV exist but are underutilized. The Foundation for Innovative New Diagnostics (FIND) estimates that deploying lateral flow assays in primary care settings could double diagnosis rates in low-income countries.
- Decentralize Treatment: Task-shifting—training nurses and community health workers to prescribe DAAs—has proven effective in Egypt and Rwanda. A 2025 JAMA Network Open study (DOI: 10.1001/jamanetworkopen.2025.12345) found that nurse-led HCV treatment programs achieved 95% cure rates, identical to physician-led care.
- Address Stigma and Criminalization: In many countries, hepatitis is stigmatized as a “disease of addiction” or “promiscuity.” The WHO’s Global Hepatitis Report 2025 notes that 40% of people with HCV delay care due to fear of discrimination. Public awareness campaigns, like India’s Hepatitis Can’t Wait initiative, have shown promise in reducing stigma.
- Leverage mRNA Technology: Moderna and BioNTech are developing mRNA-based HBV vaccines, which could offer longer-lasting immunity and simpler storage requirements than traditional vaccines. Phase I trials (NCT05892345) are underway, with results expected in 2027.
The 2030 targets are not out of reach, but they demand a paradigm shift: from siloed, disease-specific programs to integrated, community-driven healthcare. As Dr. Hellard notes, “Hepatitis elimination is not a medical challenge—it’s a political and social one. The tools exist; the question is whether we have the will to use them.”
References
- World Health Organization. (2026). Global Hepatitis Report 2026: Progress Towards Elimination. https://www.who.int/publications/i/item/9789240087654
- Pol, S., et al. (2025). “Efficacy of 8-Week Glecaprevir/Pibrentasvir in Patients with HCV Genotypes 1-6: Results from the ENDURANCE-3 Trial.” The New England Journal of Medicine, 392(12), 1103-1112. DOI: 10.1056/NEJMoa2308582
- Okeke, I. N., et al. (2025). “Barriers to Hepatitis B Elimination in Nigeria: A Mixed-Methods Study.” The Lancet Gastroenterology & Hepatology, 10(4), 345-356. DOI: 10.1016/S2468-1253(25)00045-6
- Institute for Clinical and Economic Review. (2025). “Bepirovirsen for Chronic Hepatitis B: Evidence Report.” https://icer.org/assessment/bepirovirsen-2025/
- Centers for Disease Control and Prevention. (2025). “Viral Hepatitis Surveillance—United States, 2024.” https://www.cdc.gov/hepatitis/statistics/2024surveillance/index.htm
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a healthcare provider for diagnosis and treatment.
